“Whoa! It’s like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Try 2 weeks free now

Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer

<h5>Background</h5> Evidence to support the use of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin chemotherapy regimens in people with advanced non-small-cell lung cancer is limited.</P><h5>Objective</h5> To determine if gefitinib, in combination with paclitaxel and carboplatin chemotherapy improves survival outcomes in people with advanced non-small-cell lung cancer.</P><h5>Setting</h5> This multicentre study was conducted mainly (80%) in the United States.</P><h5>Method</h5> Multicentre randomised controlled trial.</P><h5>Participants</h5> 1037 people (∼60% male, median age ∼61 years, range 26–86 years) with histologically confirmed non-small-cell lung cancer (NSCLC) and disease stage IIIa ( n = 30, 3%); IIIb without malignant pleural effusion ( n = 41, 4%); IIIb with malignant pleural effusion ( n = 127, 12%) or stage IV ( n = 834, 80%; note: information not available from all participants) with a WHO performance status of 0 ( n = 367, 35%), 1 ( n = 554, 53%) or 2 ( n = 114, 11%). People were excluded if they: had mixed NSCLC plus small-cell lung cancer; had previously received chemotherapy; had brain metastases that were newly diagnosed or had not been treated with surgery or radiation; had previously been treated for CNS metastases or spinal-cord compression http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Treatment Reviews Elsevier
Loading next page...

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy unlimited access and
personalized recommendations from
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $40/month

Try 2 weeks free now

Explore the DeepDyve Library

How DeepDyve Works

Spend time researching, not time worrying you’re buying articles that might not be useful.

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.

All the latest content is available, no embargo periods.

See the journals in your area

Simple and Affordable Pricing

14-day free trial. Cancel anytime, with a 30-day money-back guarantee.

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Best Deal — 25% off

Annual Plan

  • All the features of the Professional Plan, but for 25% off!
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

billed annually